Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT02676739
PHASE2/PHASE3

Adderall XR and Cognitive Impairment in MS

Sponsor: Sarah Morrow

View on ClinicalTrials.gov

Summary

This 12 week randomized placebo-controlled study will compare the effects of 10 mg and 20 mg of a mixed amphetamine salt, extended release medication (trade name Adderall XR) to placebo on objective measures of processing speed and memory, as well as on self-reported measures of cognition and quality of life. To be enrolled in the study, MS subjects must demonstrate impaired processing speed on the Symbol Digit Modalities Test (SDMT).

Official title: A Double-blind Placebo Controlled Study of Mixed-amphetamine Salts, Extended Release (Adderall XR) for Cognitive Impairment in MS

Key Details

Gender

All

Age Range

18 Years - 59 Years

Study Type

INTERVENTIONAL

Enrollment

180

Start Date

2016-05-20

Completion Date

2024-12

Last Updated

2024-10-17

Healthy Volunteers

No

Interventions

DRUG

Adderall XR

Locations (3)

Kaye Edmonton Clinic

Edmonton, Alberta, Canada

London Health Sciences Centre

London, Ontario, Canada

Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada